Know Cancer

forgot password

Determination of A-Protein Levels in Adult and Pediatric Brain Tumor Patients

77 Years
Open (Enrolling)
Malignant or Benign Lesions of the Central Nervous System

Thank you

Trial Information

Determination of A-Protein Levels in Adult and Pediatric Brain Tumor Patients

- Patients will be identified at the time of presentation to their neurologist,
neurosurgeon or oncologist.

- Blood or cerebrospinal fluid will be collected for this study only when they are being
collected for other reasons before and after each surgery. Samples will also be
collected after any event such as significant change in symptoms or radiographic

- Once the patients condition has been stabilized, samples will be take at regular
intervals of >= 1 month. The duration of this study is 24 months.

Inclusion Criteria:

- All patients with possible malignant or benign lesions of the central nervous system
will be included.

- There are no restrictions with respect to treatment protocols or prior therapy.

- Patients will be identified after presentation to the neurosurgical, neurological or
oncologic services at participating centers. Any patient with evidence of a central
nervous system tumor will be eligible. Individuals without evidence of CNS tumors are
also eligible, in order to provide blinded controls.

- A signed informed consent will be requested and required for participation.

- There is no age, sex, or ethnic origin restrictions in this protocol. Patients who
choose not to participate in the study will continue to have their regular care as
defined by their treating team. Patients who speak foreign languages are eligible as
long a translator can be found to ensure proper consent has been obtained.

Exclusion Criteria: There are no exclusion criteria for this study.

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

The purpose of this study is to evaluate the usefulness of a molecule called "A-Protein" in the diagnosis and evaluation of patients with central nervous system disorders.

Outcome Time Frame:

24 months

Safety Issue:


Principal Investigator

Mark W Kieran, MD,PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Institutional Review Board

Study ID:




Start Date:

June 1998

Completion Date:

February 2010

Related Keywords:

  • Malignant or Benign Lesions of the Central Nervous System
  • A-protein level
  • brain tumor
  • Brain Neoplasms



Dana Farber Cancer Institite Boston, Massachusetts  02115